Cargando…
Mode of Action of RZL-012, a New Fat-Reducing Molecule
RZL-012 (5-[3,6-dibromo-9H-carbazol-9-yl]-N,N,N-trimethylpentan-1-aminium chloride) is a novel investigational drug injected subcutaneously into fat tissues in patients with fat-related disorders (Dercum disease) or subjects seeking aesthetic changes. OBJECTIVE: Preclinical studies were undertaken t...
Autores principales: | Blaugrund, Eran, Gueta, Racheli, Zernov, Anton, Bloomenfeld, Alon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612913/ https://www.ncbi.nlm.nih.gov/pubmed/34537791 http://dx.doi.org/10.1097/DSS.0000000000003245 |
Ejemplares similares
-
Tapencarium (RZL-012) for Flank Fat Reduction: A Proof-of-Concept Study
por: Shridharani, Sachin M, et al.
Publicado: (2023) -
Efficacy and Safety of Tapencarium (RZL-012) in Submental Fat Reduction
por: Shridharani, Sachin M, et al.
Publicado: (2023) -
PI3K/AKT/mTOR Signaling Pathway Is Downregulated by Runzaoling (RZL) in Sjögren's Syndrome
por: Zeng, Ping, et al.
Publicado: (2022) -
PW01-012 – Canakinumab in patients with FMF
por: Ugurlu, S, et al.
Publicado: (2013) -
AB012. Brachytherapy for localized prostate cancer
por: Xu, Yong, et al.
Publicado: (2016)